Showing 1 - 5 results of 5 for search 'Hawk Kim', query time: 0.04s Refine Results
  1. 1
    Effect of transcript type and droplet digital polymerase chain reaction on successful treatment-free remission in chronic myeloid leukemia patients who discontinued tyrosine kinase inhibitor

    Effect of transcript type and droplet digital polymerase chain reaction on successful treatment-free remission in chronic myeloid leukemia patients who discontinued tyrosine kinas... by Hyunkyung Park, Hyeong-Joon Kim, Sang-Kyun Sohn, Yoonsuk Baik, Dongho Kim, Sung-Yeoun Lee, Jee Hyun Kong, Hawk Kim, Dong-Yeop Shin, Jae-Sook Ahn, Jinny Park, Seonyang Park, Inho Kim

    Published 2023-11-01
    Get full text
    Article
  2. 2
    Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study

    Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study by Seok Jin Kim, Jong Wook Lee, Chul Won Jung, Chang Ki Min, Bin Cho, Ho Jin Shin, Joo Seop Chung, Hawk Kim, Won Sik Lee, Young Don Joo, Deok-Hwan Yang, Hoon Kook, Hyoung Jin Kang, Hyo Seop Ahn, Sung-Soo Yoon, Sang Kyun Sohn, Yoo Hong Min, Woo-Sung Min, Hee-Sook Park, Jong Ho Won

    Published 2010-11-01
    Get full text
    Article
  3. 3
    Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study

    Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study by Sung-Eun Lee, Soo Young Choi, Hye-Young Song, Soo-Hyun Kim, Mi-Yeon Choi, Joon Seong Park, Hyeoung-Joon Kim, Sung-Hyun Kim, Dae Young Zang, Sukjoong Oh, Hawk Kim, Young Rok Do, Jae-Yong Kwak, Jeong-A Kim, Dae-Young Kim, Yeung-Chul Mun, Won Sik Lee, Myung Hee Chang, Jinny Park, Ji Hyun Kwon, Dong-Wook Kim

    Published 2016-06-01
    Get full text
    Article
  4. 4
    Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors

    Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors by Sung-Hyun Kim, Hari Menon, Saengsuree Jootar, Tapan Saikia, Jae-Yong Kwak, Sang-Kyun Sohn, Joon Seong Park, Seong Hyun Jeong, Hyeoung Joon Kim, Yeo-Kyeoung Kim, Suk Joong Oh, Hawk Kim, Dae Young Zang, Joo Seop Chung, Ho Jin Shin, Young Rok Do, Jeong-A Kim, Dae-Young Kim, Chul Won Choi, Sahee Park, Hye Lin Park, Gong Yeal Lee, Dae Jin Cho, Jae Soo Shin, Dong-Wook Kim

    Published 2014-07-01
    Get full text
    Article
  5. 5
    A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome‐positive chronic myeloid leukemia in chronic phase: ENESTKorea

    A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome‐positive chronic myeloid leukemia in chronic phase: ENESTKorea by Junghoon Shin, Youngil Koh, Seo Hyun Yoon, Joo‐Youn Cho, Dae‐Young Kim, Kyoo‐Hyung Lee, Hyeong‐Joon Kim, Jae‐Sook Ahn, Yeo‐Kyeoung Kim, Jinny Park, Sang‐Kyun Sohn, Joon Ho Moon, Yoo Jin Lee, Seonghae Yoon, Jeong‐Ok Lee, June‐Won Cheong, Kyoung Ha Kim, Sung‐Hyun Kim, Hoon‐Gu Kim, Hawk Kim, Seung‐Hyun Nam, Young Rok Do, Sang‐Gon Park, Seong Kyu Park, Sung Hwa Bae, Hun Ho Song, Dong‐Yeop Shin, Doyeun Oh, Min Kyoung Kim, Chul Won Jung, Seonyang Park, Inho Kim

    Published 2018-05-01
    Get full text
    Article

Search Tools: